Drugs · acquisition-cost intelligence
tretinoin
· ingredient tretinoinRetinoids for cancer treatment· TRETINOIN 1 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.94183
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other tretinoin products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Retin-A | $0.86759 | −$0.07420 |
| tretinoin | $1.26 | +$0.31660 |
| Tretinoin | $3.04 | +$2.09 |
| Atralin | $4.23 | +$3.28 |
| Clindamycin Phosphate 1.2% and Tretinoin 0.025% | $4.30 | +$3.36 |
| TRI-LUMA | $7.82 | +$6.88 |
| Tretinoin (Microsphere) | $8.71 | +$7.77 |
| Tretinoin | $9.65 | +$8.71 |
Medicare Part D coverage · CY2026
On 309 plan formularies · typical tier 4
Prior auth 92% · Step therapy 0% · Quantity limit 58% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.